Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 15/20 | 0.42 |
| ▸ | SCN1A | P35498 | 14/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 12/20 | 0.42 |
| ▸ | SCN1B | Q07699 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783350 | 0.90 | SCN1A (0.44) | SCN8ASCN1ASCN5ASCN1BMEN1 | |
| SCHEMBL21783441 | 0.78 | SCN8A (0.43) | SCN8ASCN1ASCN5ASCN1BMEN1 | |
| SCHEMBL21783342 | 0.73 | SCN8A (0.38) | SCN8ASCN1ASCN5ASCN1BMEN1 | |
| SCHEMBL20256235 | 0.67 | SCN8A (0.44) | SCN8ASCN1ASCN5ASCN1B | |
| SCHEMBL20256531 | 0.67 | SCN8A (0.55) | SCN8ASCN1ASCN5ASCN1B | |
| SCHEMBL21783325 | 0.65 | CASP6 (0.44) | SCN8ASCN1ASCN5ASCN1BMEN1 | |
| SCHEMBL20256344 | 0.65 | SCN8A (0.46) | SCN8ASCN1ASCN5ASCN1B | |
| SCHEMBL19634164 | 0.65 | SCN1A (0.35) | SCN8ASCN1ASCN5ASCN1BSCN9A | |
| SCHEMBL20256561 | 0.64 | SCN8A (0.43) | SCN8ASCN1ASCN5ASCN1B | |
| SCHEMBL20256303 | 0.63 | KDM4E (0.39) | SCN8ASCN1ASCN5ASCN1BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020047323-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |